KYNB
Kyntra Bio, Inc.
NASDAQ: KYNB · HEALTHCARE · BIOTECHNOLOGY
$7.27
+3.12% today
Updated 2026-04-30
Market cap
$28.37M
P/E ratio
—
P/S ratio
4.41x
EPS (TTM)
$-14.40
Dividend yield
—
52W range
$5 – $13
Volume
0.0M
Kyntra Bio, Inc. (KYNB) Financial statements
SEC filings — annual and quarterly data.
Profit margin
2,849.00%
Operating margin
-1,059.00%
ROE
0.00%
ROA
-17.00%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | $65.93M | $-32.57M | -12.57% | -41.29% | -49.40% |
| 2013 | $102.17M | $-14.94M | 16.11% | -7.78% | -14.63% |
| 2014 | $137.60M | $-59.50M | -9.59% | -36.41% | -43.24% |
| 2015 | $180.83M | $-85.78M | -18.39% | -42.93% | -47.44% |
| 2016 | $179.58M | $-61.68M | -4.25% | -29.88% | -34.35% |
| 2017 | $125.67M | $-126.20M | -56.38% | -97.57% | -100.43% |
| 2018 | $212.96M | $-86.42M | -10.74% | -40.71% | -40.58% |
| 2019 | $256.58M | $-76.97M | 99.55% | -34.81% | -30.00% |
| 2020 | $176.32M | $-189.29M | 94.97% | -108.83% | -107.36% |
| 2021 | $235.31M | $-290.02M | -90.89% | -122.62% | -123.25% |
| 2022 | $140.73M | $-293.65M | 85.59% | -213.90% | -208.66% |
| 2023 | $46.80M | $-284.23M | 91.53% | -689.53% | -607.29% |
| 2024 | $29.62M | $-47.58M | 47.47% | -507.80% | -160.63% |
| 2025 | $6.44M | $183.45M | 91.37% | -712.66% | 2,848.63% |